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Abstract
Background—We evaluated whether cardiac troponin T (cTnT) measured with a new highly
sensitive assay was associated with incident coronary heart disease (CHD), mortality, and
hospitalization for heart failure (HF) in a general population of participants in the Atherosclerosis
Risk in Communities (ARIC) Study.
Methods and Results—Associations between increasing cTnT levels and CHD, mortality, and
HF hospitalization were evaluated using Cox proportional-hazards models adjusted for traditional
CHD risk factors, kidney function, high-sensitivity C-reactive protein (hs-CRP), and N-terminal
pro–B-type natriuretic peptide (NT-proBNP) in 9,698 participants aged 54–74 years who at
baseline were free from CHD and stroke (and HF in the HF analysis). Measurable cTnT levels
(≥0.003 μg/L) were detected in 66.5% of individuals. In fully adjusted models, compared with
participants with undetectable levels, those with cTnT levels in the highest category (≥0.014 μg/L,
7.4% of the ARIC population) had significantly increased risk for CHD (hazard ratio [HR] 2.29,
95% confidence interval [CI] 1.81–2.89), fatal CHD (HR 7.59, 95% CI 3.78–15.25), total
mortality (HR 3.96, 95% CI 3.21–4.88), and HF (HR 5.95, 95% CI 4.47–7.92). Even minimally
elevated cTnT (≥0.003 μg/L) was associated with increased risk for mortality and HF (p<0.05).
Adding cTnT to traditional risk factors improved risk prediction parameters; the improvements
were similar to those with NT-proBNP and better than that with the addition of hs-CRP.
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Conclusions—cTnT detectable with a highly sensitive assay was associated with incident CHD,
mortality, and HF in individuals from a general population without known CHD/stroke.
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Cardiac troponin T (cTnT) and troponin I are the biomarkers recommended for diagnosis of
a myocardial infarction (MI) and in the setting of an acute coronary syndrome.1 Cardiac
troponin, which is released in response to cardiomyocyte necrosis, has been independently
associated with adverse outcomes following acute coronary syndrome,2 in patients with
chronic heart failure (HF),3 and in the general population although cTnT levels are
detectable in only a small fraction of the general population using current assays.4–8
A precommercial highly sensitive cTnT assay (hs-cTnT) can detect 10-fold lower
concentrations than currently available 4th-generation assays. Using this assay, cTnT levels
below the detection range of standard assays were independently associated with adverse
cardiovascular events in patients with HF9 or stable coronary heart disease (CHD).10 The
clinical significance of detectable cTnT using the new assay in the general population is not
known.
We determined prevalence of measurable cTnT with the new assay; evaluated associations
of cTnT with CHD, death, and HF; and determined whether cTnT improves risk prediction
for these outcomes in participants without cardiovascular disease (CVD) (n=9,698) in the
Atherosclerosis Risk in Communities (ARIC) Study. Further, we performed limited
comparisons between cTnT, N-terminal pro–B-type natriuretic peptide (NT-proBNP), and
high-sensitivity C-reactive protein (hs-CRP) with respect to risk prediction.
METHODS
More detailed Methods are described in the Supplementary Material. cTnT levels were
measured with a novel precommercial highly sensitive assay (Elecsys Troponin T [Roche
Diagnostics, Indianapolis, IN]). The lower limit of detection of the novel assay is 0.003 μg/
L. The lower limit of detection of the currently available clinically used assay is 0.01 μg/L,
which corresponds to 0.03 μg/L with the high-sensitivity assay (i.e., the new assay has 10-
fold increased detection).10 Outcomes assessed were incident CHD events (fatal CHD,
definite or probable MI, coronary revascularization), all-cause mortality, and hospitalization
for HF (ICD-9 code 428).
Statistical Methods
The distribution and percentile of cTnT were determined from all ARIC participants with
measurements, including those with prevalent CVD, to reflect more accurately the general
population. All other analyses were performed only in participants without CVD (HF
analyses also excluded those with prevalent HF; also see Supplementary Material).
We modeled cTnT as both a categorical and a continuous variable. For the categorical
analyses, the 33.5% with undetectable levels were the reference group (Group 1). The
remaining 66.5% were split into approximate thirds: cTnT levels 0.003–0.005 μg/L (Group
2), 0.006–0.008 μg/L (Group 3), and higher levels divided at approximately the 90th
percentile of the ARIC population (Group 4: 0.009–0.013 μg/L; Group 5: ≥0.014 μg/L),
which incidentally corresponded to the 99th percentile value specified by the manufacturer.
Because of confounding by age, gender, and race, we present age-, gender-, and race-
adjusted survival curves by cTnT level; adjustments were stratified by the 5 cTnT categories
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to fit product-limit survival functions for each age/gender/race combination and applying the
method of predicted marginals11 to obtain adjusted survival curves. Age-, gender-, and race-
adjusted events rates were estimated by Poisson regression. Associations between cTnT
categories and outcomes were determined with Cox proportional-hazards models. The basic
model (model 1) adjusted for age, gender, and race. Model 2 adjusted for components of the
ARIC CHD Risk Score (ACRS): all components of model 1, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), systolic blood pressure, antihypertensive medication use,
smoking status, and presence of diabetes (fasting blood glucose >126 mg/dL or antidiabetic
medication use).12 Coefficients for ACRS components were derived specifically for this
dataset. Model 3 adjusted for ACRS plus hs-CRP, NT-proBNP, and estimated glomerular
filtration rate (eGFR). We also analyzed associations between cTnT and outcomes using a
continuous piecewise linear model, which demonstrated a better fit for incident CHD than
polynomial or log-transformed models. In continuous models, undetectable levels were
assigned a level of 0.0015 μg/L (half the lower limit of detection, as suggested by D’Angelo
et al13).
To analyze the incremental value of cTnT in risk prediction, areas under the receiver
operating characteristic curve (AUC), net reclassification improvement (NRI), clinical NRI
(NRI in the intermediate-risk group), and integrated discrimination improvement (IDI) were
calculated for the overall study population and by gender for 10-year follow-up.
Bootstrapping was performed to furnish 95% confidence intervals (CIs) for the differences
between models. Model calibration was assessed by Grønnesby–Borgan goodness-of-fit test.
The base model for CHD risk prediction was ACRS alone; the extended model added cTnT
as a continuous variable using the piecewise linear model described above. Although no risk
prediction models for total mortality and HF hospitalizations are validated in ARIC, we
added body mass index (BMI), left ventricular hypertrophy (LVH), and creatinine to ACRS
as the base model for prediction of mortality and HF hospitalization as these additional
variables were associated with mortality and HF in other studies.14,15 We created similar
risk categories (as for CHD risk prediction) to estimate NRI and clinical NRI. Finally, we
added hs-CRP and NT-proBNP to the risk prediction models for CHD, mortality, and HF to
compare cTnT with these other markers.
RESULTS
cTnT was detectable in 6,440 individuals (66.5%) and ≥0.014 μg/L in 715 individuals
(7.4%). The 99th percentile for cTnT in the entire ARIC population was 0.03 μg/L
(corresponding to the lower limit of detection of the current, clinically used assay) and 0.027
μg/L in participants without CVD. Thus, <1% of the ARIC population had cTnT levels that
would have been detected by the currently used assay. Detectable cTnT levels ranged from
0.003 μg/L to 0.340 μg/L. The distribution of cTnT by gender is shown in Figure 1. cTnT
was detectable in 83% of men, compared with ~55% of women; 13% of men and 3% of
women were in the highest cTnT group. Log-transformed cTnT levels correlated with log-
transformed NT-proBNP levels; after excluding individuals with undetectable cTnT and
NT-proBNP levels, Pearson’s correlation coefficients were 0.22, 0.32, and 0.25 for the
overall group, men, and women, respectively (p<0.0001 for all).
Table 1 shows baseline demographic characteristics by cTnT category. Individuals with
higher cTnT levels were older; were more likely to be male, hypertensive, and diabetic;
were less likely to be current smokers; had lower eGFR, total cholesterol, and HDL-C; and
had higher triglyceride, hs-CRP, and NT-proBNP levels.
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Associations of Troponin Levels with CHD, Mortality, and HF Hospitalization
All hazard ratios (HRs) presented for associations between cTnT and outcomes used the
undetectable cTnT group as the referent. Relationships between cTnT and each outcome
were not statistically different across time periods (<1 year, 1–3 years, >3 years); therefore,
the proportional-hazards assumption was not rejected. Age-, gender-, and race-adjusted
event rates are presented in Supplemental Table 1. Overall, event rates increased with
increasing cTnT levels, except CHD in men, for which the increase was apparent only in the
highest cTnT category.
CHD—cTnT values in the highest category were associated with incident CHD events
(n=983 [117 CHD deaths, 454 definite or probable MIs, and 916 definite or probable MIs or
coronary revascularizations]; mean follow-up 9.4 years) in the overall cohort (Table 2), as
well as in men and women (Supplemental Tables 2 and 3) considered separately.
Associations of cTnT with fatal CHD (HR 7.59, 95% CI 3.78–15.25 for Group 5) were
consistently stronger than associations with MI+revascularization (data not presented).
All-cause mortality—Measurable cTnT had a graded association with death (n=1,210;
mean follow-up 9.9 years; Figure 2B) that persisted even in the fully adjusted model (HR
1.37, 95% CI 1.14–1.65 in Group 2; HR 3.96, 95% CI 3.21–4.88 in Group 5 [Table 2]).
Associations between cTnT and mortality remained significant when men and women were
evaluated separately (Supplemental Tables 2 and 3).
HF Hospitalization—Over a mean follow-up of 9.7 years, 668 HF hospitalizations
occurred; ~3% (n=105) of individuals with undetectable cTnT had HF events compared with
25% (n=159) of individuals in the highest cTnT group. Detectable cTnT was associated with
HF hospitalization even in the fully adjusted model; for the lowest and highest detectable
cTnT categories, HRs were 1.48 (95% CI 1.14–1.92) and 5.95 (95% CI 4.47–7.92),
respectively. Associations between cTnT and HF hospitalization remained significant at all
detectable cTnT levels for men, while in women the association was significant at levels
≥0.006 μg/L (Supplemental Tables 2 and 3).
Figure 2 shows cumulative incidence curves adjusted for age, gender, and race, and Figure 3
shows the continuous hazards functions, adjusted for ACRS components (model 2), of cTnT
with total CHD events, all-cause mortality, and HF hospitalization. Overall, associations
between cTnT and events were strongest for HF hospitalization, intermediate for all-cause
mortality, and least robust for total CHD.
Troponin T and Risk Prediction
Adding cTnT to ACRS reclassified 17.9% (n=1737) of the overall population for CHD risk
prediction: 10.8% to lower risk and 7.1% to higher risk (Supplemental Table 4). For all
CHD and hard CHD, adding cTnT (as a continuous variable) to an ACRS-based model
significantly improved the AUC adjusted for optimism, NRI, clinical NRI, and IDI in the
overall population and in women; in men, all parameters except for NRI for all CHD were
significantly improved (Table 3). Improvements in statistical parameters for hard CHD
prediction were generally better than for all CHD. Calibration of the models assessed by the
Grønnesby–Borgan test indicated improved model fit with the addition of cTnT for hard
CHD in the overall group and for all CHD in women. For mortality and HF hospitalization,
adding cTnT to the base model (ACRS+BMI+LVH+creatinine) improved the AUC, NRI,
clinical NRI, and IDI in all groups, and in general the improvements were greater in
magnitude than for all CHD (no statistical comparisons performed). The receiver operator
characteristics curves for the various outcomes are provided in the supplement
(Supplemental Figure 1). In limited exploratory analyses, addition of either cTnT or NT-
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proBNP appeared to be superior to adding hs-CRP for improving risk prediction for all
outcomes (Supplemental Tables 5–7).
DISCUSSION
In our analysis, cTnT measured with a new high-sensitivity assay had strong associations
with CHD, mortality, and HF in a general population of middle-aged to older adults without
CVD. The new assay detected cTnT in 66.5% of these individuals, the vast majority of
whom had levels that would have been undetectable by the currently available, clinically
used 4th-generation assay. Only 65 individuals (<1% of the ARIC population) had cTnT
levels ≥0.03 μg/L (i.e., detectable using the currently used assay), consistent with reported
detectable levels in <1% of the general population5 and 4.1% of the elderly population.6
Prior studies using this hs-cTnT assay have reported associations with adverse
cardiovascular outcomes in individuals with chronic HF9 and stable CHD,10 and we now
extend the findings to a general population aged 54–74 years. Among the outcomes tested,
associations were strong with fatal CHD, all-cause mortality, and HF hospitalization. Of the
CHD outcomes, the association with fatal CHD was strongest, and associations with
nonfatal CHD events, including MI and revascularization, were weaker. However, relatively
few fatal CHD events occurred; hence, when all CHD events were considered together, the
association was weaker than with all-cause mortality and HF. Metrics of risk prediction,
including AUC, NRI, and IDI, were also more robust for mortality and HF than for CHD
(Table 3). In exploratory analyses, improvements in risk prediction for CHD, mortality, and
HF when cTnT was added to risk prediction models were similar to those provided by NT-
proBNP and larger than those for hs-CRP. In summary, our findings suggest that cTnT may
be an important marker in the prediction of hard CHD, mortality, and HF.
Our results are concordant with those of 2 other population studies, the Cardiovascular
Health Study (CHS)16 and the Dallas Heart Study (DHS),17 which were published after
submission of this report; all 3 studies used the same assay. The ARIC results are most
similar to those of CHS (average age ~10 years older than ARIC), in which 66% of
participants had detectable cTnT with the new assay.16 Although overall only 25% of DHS
participants had detectable levels, >50% were aged <50 years; 56% of participants aged 60–
65 had detectable levels.17 All 3 studies found strong associations with mortality. The
younger age and greater number of ARIC participants may have contributed to the larger
NRI for mortality and HF than in CHS. The prevalence of detectable cTnT with the high-
sensitivity assay is clearly distinct from the “sensitive” troponin I assay used by
Blankenberg et al., which detected levels in <2% of population cohorts.8
The weaker association observed with nonfatal CHD events seems counter to findings in
patients with acute coronary syndromes, in whom elevated cTnT level is a strong marker for
risk for future MI.18,19 However, small elevations in cTnT had no association with short-
term risk for MI in asymptomatic individuals with stable CHD10; this, taken together with
our findings, suggests that the risk from low detectable cTnT levels in asymptomatic
subjects may be mediated through mechanisms other than or in addition to
atherothrombosis. These mechanisms, which are not fully understood, may result from
troponin release from cardiac myocytes due to asymptomatic ischemia, coronary
microvascular dysfunction, apoptosis, or subclinical cardiac structural or functional
abnormalities. Troponin I levels measured with a highly sensitive assay increased with
reversible ischemia detected by nuclear perfusion imaging,20 supporting the notion that
subclinical ischemia could induce troponin release. However, in another study that used the
hs-cTnT assay, cTnT levels did not change with exercise- or pharmacological stress–
induced ischemia,21 again suggesting that factors other than ischemia contribute
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significantly to the risk associated with cTnT. Coronary microvascular dysfunction, which
occurs in hypertension, diabetes, and LVH, is another potential cause for elevated
circulating troponin levels22 and may mediate, in part, the associations observed with HF
events. Troponin is eliminated from the circulation via renal clearance; therefore, as
glomerular filtration declines, troponin levels may increase. While this was true in ARIC,
the associations with outcomes remained strong even after adjustment for eGFR. Therefore,
the mechanisms underlying elevated troponin levels may be several, and it is unclear which
mechanisms are related to the outcomes observed in our study.
Clinical and Therapeutic Implications
The strength of the associations between cTnT and the various outcomes has several
potential implications. First, troponin levels above 99th percentile values have been
recommended for diagnosis of MI.1 The 99th percentile value for cTnT in our study (0.03
μg/L) was far higher than that published by the manufacturer (0.014 μg/L), and 7% of the
ARIC population had levels ≥0.014 μg/L. Januzzi et al.23 reported (using the manufacturer-
determined 99th percentile cutpoint) that the high-sensitivity assay had a lower positive
predictive value (38%) than the conventional assay (67–72%), suggesting that false positives
were higher with the high-sensitivity assay. If the 99th percentile identified in a population
study such as ARIC were used, the estimated predictive value may be different. The
diagnostic criteria may need to be revised to include both absolute cTnT level and rise and
fall in cTnT level when the high-sensitivity assay is used.24 Conversely, undetectable cTnT
with the new assay may have superior negative predictive value, which will need further
study.
cTnT modestly improves CHD risk prediction, and therapies such as statin and/or aspirin
could hypothetically be considered for individuals reclassified as higher risk with cTnT.
However, although statins reduce CHD events in patients with traditional risk factors such
as hypertension,25 statins have not shown benefit in some high-risk populations such as
patients with HF26 or end-stage renal disease.27 Furthermore, a recent study in individuals
with diabetes suggested that cTnT levels did not change significantly with either intensive or
standard risk factor management.28
The stronger association of cTnT with death and HF than with CHD suggests that this
biomarker predicts structural heart disease events to a greater extent than atherosclerotic
events. Therefore, strategies aimed to prevent CHD may have smaller effects than strategies
aimed to prevent progression of structural heart disease. As HF prevalence and incidence
continue to increase, markers such as cTnT may conceivably identify high-risk individuals
and allow early initiation of preventive strategies. Better understanding of the adverse
mechanisms/process(es) that cTnT marks or mediates may be useful in targeting therapies,
but ultimately clinical trials will be needed to examine if risk can be modified.
Limitations—Validated mortality and HF risk prediction models have not yet been
developed in ARIC; therefore, we added BMI, creatinine, and LVH to the ACRS for use as
the base model. However, AUCs were greater for both mortality (0.719) and HF (0.749)
than for all CHD (0.715). We do not know if cTnT would have added to risk prediction with
the addition of other biomarkers or clinical variables including echocardiography (which
was not available) to the ACRS.
Conclusion
cTnT measured with a novel highly sensitive cTnT assay was detectable in the majority of
middle-aged individuals without prevalent CVD. Even slight elevations were strongly
associated with death, especially CHD death, and HF hospitalization. Although there was an
Saunders et al. Page 6













association between cTnT and MI, it was less pronounced than that for the other endpoints
assessed. Whether the risk for CHD, mortality, and HF hospitalization associated with
measurable cTnT in individuals without prior CVD is modifiable is unknown and requires
further study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Histogram showing gender-specific distribution of cardiac troponin T (cTnT) assay in the
Atherosclerosis Risk in Communities (ARIC) sample.
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Age-, race-, and gender-adjusted survival curves assessing the time to event across cTnT
categories.
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Continuous hazard functions of cTnT with total coronary heart disease, all-cause mortality,
and heart failure hospitalizations for the overall group (A), in women (B), and in men (C),
adjusted for age, race, gender (in the overall analyses), and traditional risk factors (total
cholesterol, high-density lipoprotein cholesterol [HDL-C], systolic blood pressure, use of
antihypertensive medications, smoking status, and presence of diabetes or the use of
antidiabetic medications).
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